×
Virax Biolabs Group Long Term Debt 2022-2024 | VRAX
Prices
Financials
Revenue & Profit
Assets & Liabilities
Margins
Price Ratios
Other Ratios
Other Metrics
Total Assets
Cash on Hand
Long Term Debt
Total Liabilities
Share Holder Equity
Virax Biolabs Group long term debt from 2022 to 2024. Long term debt can be defined as the sum of all long term debt fields.
View More
Virax Biolabs Group Long Term Debt 2022-2024 | VRAX
Prices
Financials
Revenue & Profit
Assets & Liabilities
Margins
Price Ratios
Other Ratios
Other Metrics
Total Assets
Cash on Hand
Long Term Debt
Total Liabilities
Share Holder Equity
Virax Biolabs Group long term debt from 2022 to 2024. Long term debt can be defined as the sum of all long term debt fields.
Related Stocks
Company Name
Market
Cap
AstraZeneca (AZN)
$222.7B
Amgen (AMGN)
$161.5B
Gilead Sciences (GILD)
$142.5B
Vertex Pharmaceuticals (VRTX)
$123.1B
Bristol Myers Squibb (BMY)
$98.7B
GSK (GSK)
$81B
CSL (CSLLY)
$78.2B
Regeneron Pharmaceuticals (REGN)
$60.4B
Alnylam Pharmaceuticals (ALNY)
$42.1B
Argenex SE (ARGX)
$34.4B
BioNTech SE (BNTX)
$27.4B
Royalty Pharma (RPRX)
$20.3B
Biogen (BIIB)
$19.8B
Insmed (INSM)
$18.3B
Illumina (ILMN)
$15.8B
Genmab (GNMSF)
$14B
Genmab (GMAB)
$14B
Incyte (INCY)
$13.6B
Moderna (MRNA)
$13.3B
Exelixis (EXEL)
$12.3B
BioMarin Pharmaceutical (BMRN)
$11.3B
QIAGEN (QGEN)
$10.8B
Ascendis Pharma (ASND)
$10.8B
Swedish Orphan Biovitrum (BIOVF)
$10.4B
Exact Sciences (EXAS)
$10.1B
Verona Pharma American Depositary Share (VRNA)
$8.9B
Bio-Techne Corp (TECH)
$8.5B
Blueprint Medicines (BPMC)
$8.4B
Regencell Bioscience Holdings (RGC)
$8.2B
Roivant Sciences (ROIV)
$7.9B